ENSC vs. SNGX, PTPI, SEEL, ZVSA, CYCC, ALZN, EVOK, GOVX, XCUR, and THAR
Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Soligenix (SNGX), Petros Pharmaceuticals (PTPI), Seelos Therapeutics (SEEL), ZyVersa Therapeutics (ZVSA), Cyclacel Pharmaceuticals (CYCC), Alzamend Neuro (ALZN), Evoke Pharma (EVOK), GeoVax Labs (GOVX), Exicure (XCUR), and Tharimmune (THAR). These companies are all part of the "pharmaceutical preparations" industry.
Ensysce Biosciences (NASDAQ:ENSC) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 52.7% of Ensysce Biosciences shares are held by insiders. Comparatively, 1.4% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Ensysce Biosciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.
In the previous week, Soligenix had 8 more articles in the media than Ensysce Biosciences. MarketBeat recorded 9 mentions for Soligenix and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.76 beat Soligenix's score of 0.55 indicating that Ensysce Biosciences is being referred to more favorably in the media.
Ensysce Biosciences currently has a consensus price target of $7.00, indicating a potential upside of 1,047.54%. Soligenix has a consensus price target of $3.00, indicating a potential upside of 717.88%. Given Ensysce Biosciences' higher possible upside, research analysts plainly believe Ensysce Biosciences is more favorable than Soligenix.
Soligenix has lower revenue, but higher earnings than Ensysce Biosciences. Soligenix is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.
Ensysce Biosciences has a net margin of -660.96% compared to Soligenix's net margin of -1,025.66%. Soligenix's return on equity of -198.36% beat Ensysce Biosciences' return on equity.
Soligenix received 275 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote.
Summary
Soligenix beats Ensysce Biosciences on 9 of the 17 factors compared between the two stocks.
Get Ensysce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ensysce Biosciences Competitors List
Related Companies and Tools
